Anemia is not part of the normal aging process and should trigger a workup for myeloid neoplasms.Barzi A, Sekeres MA. Cleve Clin J Med. 2010;77(1):37-44
When left untreated, MDS-related anemia can have a severe impact on quality of life and cause significant morbidity and mortality.Germing U et al. Hemasphere. 2019;3(6):e314.
Early assessment and investigation of the underlying causes of anemia are essential to improve long-term outcomes.Germing U et al. Hemasphere. 2019;3(6):e314.
Anemia is a frequent condition in the elderly. The cause of anemia is unexplained in one third of cases, and it may be attributed to myeloid neoplasms.Stauder R. Blood. 2018;131:505-514. Alvarez-Payares JC et al. Cureus. 2021;13:e19971.
MDS should be suspected in elderly patients with isolated, unexplained anemia. About 1 in 6 patients with unexplained anemia has findings compatible with MDS.McDonald L et al. Blood. 2018;132:5515-5515. Hasserjian RP et al. Blood. 2023;142:2247-2257. Foran JM, Shammo JM. Am J Med. 2012;125(suppl):S6-S13.
Prognostic scoring allows assessment of disease severity. Risk stratification is important to understand the disease trajectory and enable a tailored clinical approach.Hasserjian RP et al. Blood. 2023;142:2247-2257. Platzbecker U et al. Leukemia. 2021;35:2182-2198.
MDS-related anemia shortens patients’ length and quality of life. Chronic anemia and transfusion dependence are the main clinical challenges in lower-risk MDS.Platzbecker U et al. Leukemia. 2021;35:2182-2198. Oliva EN et al. Blood Rev. 2021;50:100851.
* This video is sponsored by Bristol Myers Squibb. The speaker has been compensated for his time.
Diagnosing MDS requires an extensive series of tests, but it is also important to have a high clinical suspicion to identify risk factors for developing MDS, such as advancing age.Hasserjian RP et al. Blood. 2023;142:2247-2257. Sekeres MA. Hematol Oncol Clin North Am. 2010;24:287-294.
The site will assist U.S. healthcare providers in caring for patients and conducting research with BMS medicines.
